2446-23-3 Usage
Description
4-Chlorodehydromethyltestosterone (CDMT; brand name Oral Turinabol), also known as Chlorodehydromethyltestosterone, is an anabolic–androgenic steroid (AAS) and a derivative of dehydrochloromethyltestosterone. It is an off-white solid with a role as an androgen. CDMT is used for hormone replacement therapy in men suffering from androgen deficiency or in severe cases of catabolism. It is regulated as a Schedule III compound in the United States and is intended for research and forensic applications.
Uses
Used in Athletic Performance Enhancement:
4-Chlorodehydromethyltestosterone is used as a performance-enhancing drug for athletes, as it can produce quality gains in muscle mass and strength. These gains, however, are not as dramatic or quick as those achieved with aromatizable or more androgenic oral steroids.
Used in Hormone Replacement Therapy:
In the medical field, 4-Chlorodehydromethyltestosterone is used as a hormone replacement therapy for men suffering from androgen deficiency. It helps in addressing the issues related to low androgen levels and supports overall health and well-being.
Used in Research and Forensic Applications:
As an analytical reference standard, 4-Chlorodehydromethyltestosterone is utilized in research and forensic applications to study the effects and implications of anabolic steroids on human performance and health.
Used in Pharmaceutical Industry:
4-Chlorodehydromethyltestosterone is used in the pharmaceutical industry for the development and production of medications aimed at treating androgen deficiency and related conditions. Its anabolic and androgenic properties make it a valuable compound in the development of hormone replacement therapies and other related medications.
History
4-Chlorodehydromethyltestosterone is an anabolic steroid developed in the 1960s, a highly competitive time for the Olympics and national level sports, the East German experts were looking for effective steroids that would circumvent these sports'drug testing policies. The product was introduced for clinical use in 1965 and remained in use until 1994, when production was discontinued.
Safety Profile
4-chlorodehydromethyltestosterone (known as oral turinabol) is a potent and unique anabolic steroid that was synthesized in 1962 in East Germany. Steroid has a very high safety rating for many decades, both among men, women and even children. Increases body weight without side effects (Hinkel, 1966; Petzold et al., 1969).
Check Digit Verification of cas no
The CAS Registry Mumber 2446-23-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,4,4 and 6 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 2446-23:
(6*2)+(5*4)+(4*4)+(3*6)+(2*2)+(1*3)=73
73 % 10 = 3
So 2446-23-3 is a valid CAS Registry Number.
InChI:InChI=1/C20H27ClO2/c1-18-9-8-16(22)17(21)15(18)5-4-12-13(18)6-10-19(2)14(12)7-11-20(19,3)23/h8-9,12-14,23H,4-7,10-11H2,1-3H3/t12-,13+,14+,18-,19+,20+/m1/s1
2446-23-3Relevant articles and documents
Metabolism of anabolic steroids in humans: Synthesis of 6β-hydroxy metabolites of 4-chloro-1,2-dehydro-17α-methyltestosterone, fluoxymesterone, and metandienone
Schaenzer, Willi
, p. 353 - 366 (2007/10/02)
Hydroxylation at position 6β of testosterone I (17β-hydroxyandrost-4- en-3-one) and the anabolic steroids 17α-methyltestosterone II (17β-hydroxy- 17α-methylandrost-4-en-3-one), metandienone III (17β-hydroxy-17α- methylandrosta-1,4-dien-3-one), 4-chloro-1,2-dehydro-17α-methyltestosterone IV (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one), and fluoxymesterone V (9-fluoro-11β, 17β-dihydroxy-17a-methylandrost-4-en-3- one) was achieved via light-induced autooxidation of the corresponding trimethylsilyl 3,5-dienol ethers dissolved in isopropanol or ethanol. The reaction further yielded the 6α-hydroxy isomer in low amounts. The 6β- hydroxy isomers of I-V and the 6α-hydroxy isomers of I, III, and IV were isolated and characterized by 1H and 13C NMR, high-performance liquid chromatography, gas chromatography, and mass spectrometry. Human excretion studies with single administered doses of boldenone (17β-hydroxyandrosta- 1,4-dien-3-one), 4-chloro-1,2-dehydro-17α-methyltestosterone, fluoxymesterone, metandienone, 17α-methyltestosterone, and [16,16,17- 2H3]testosterone showed that 6β-hydroxylation is the major metabolic pathway in the metabolism of 4-chloro-1,2-dehydro-17α-methyltestosterone, fluoxymesterone, and metandienone, whereas for boldenone, 17α- methyltestosterone, and testosterone, 6β hydroxylation is negligable.
This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.